Clinical IGSP-CHOP Boston
NCT00428831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2013-12-20
Summary
The main purpose of this study is to look at relationships between types of flu viruses and characteristics of infected patients, including vaccination status, organ system involvement, and disease severity. In this study, 500 patients with respiratory illnesses will have nose/throat fluid samples collected. At Children's Hospital Boston, patients 30 days to 5 years of age will be recruited; at Beth Israel Deaconess Medical Center, patients of any age will be eligible. The researchers will compare the symptoms of infection by similar flu virus types and look at differences in the flu virus types between the 2 age groups of patients. The researchers will also look at whether any flu virus types first show up in the children prior to infecting the adults. Hopefully this study will improve understanding of how flu viruses develop, spread, and cause disease. This information may help the development of more effective flu vaccines, prevention measures, and treatments.
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Min Age
- 30 Days
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-02-28
- Primary Completion
- 2008-09-30
- Completion
- 2008-09-30
Countries
- United States
Study Locations
More Related Trials
-
Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine
NCT00559975 ·Status: COMPLETED ·Phase: PHASE1
-
Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor
NCT03590808 ·Status: COMPLETED ·Phase: NA
-
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
NCT02133781 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study of Genotypic Analysis
NCT00421837 ·Status: COMPLETED
-
The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
NCT03023553 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00616928 ·Status: COMPLETED ·Phase: PHASE3
-
B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
NCT03020498 ·Status: COMPLETED ·Phase: PHASE4
-
Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China
NCT00760500 ·Status: COMPLETED
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
NCT00998803 ·Status: COMPLETED
-
Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
NCT05027932 ·Status: COMPLETED ·Phase: PHASE1
-
Influenza Immunity Against Pandemic Respiratory Virus
NCT00138281 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
NCT01788228 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
NCT01236040 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects
NCT00522236 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults
NCT01750814 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
NCT00258830 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079 ·Status: COMPLETED
-
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
NCT02539108 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults
NCT02027233 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
NCT01691326 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Influenza Virus Infection in Children Hospitalized in Spain in Two Consecutive Influenza Seasons
NCT04008823 ·Status: COMPLETED
-
Proteomic Profiling for Influenza Vaccination - FluMist
NCT00385281 ·Status: COMPLETED ·Phase: PHASE4
-
Respiratory Virus Hospitalization Study (FLU 003 Plus)
NCT01056185 ·Status: COMPLETED
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
NCT02222870 ·Status: COMPLETED ·Phase: PHASE4